- Home
- HYFM vs PRTG Comparison
HYFM vs PRTG Comparison
Compare HYFM & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- PRTG
- Stock Information
- Founded
- HYFM 1977
- PRTG 1973
- Country
- HYFM United States
- PRTG British Virgin Islands
- Employees
- HYFM N/A
- PRTG N/A
- Industry
- HYFM Industrial Machinery/Components
- PRTG Oil & Gas Production
- Sector
- HYFM Industrials
- PRTG Energy
- Exchange
- HYFM Nasdaq
- PRTG Nasdaq
- Market Cap
- HYFM 17.3M
- PRTG 17.7M
- IPO Year
- HYFM 2020
- PRTG N/A
- Fundamental
- Price
- HYFM $4.37
- PRTG $9.11
- Analyst Decision
- HYFM
- PRTG
- Analyst Count
- HYFM 0
- PRTG 0
- Target Price
- HYFM N/A
- PRTG N/A
- AVG Volume (30 Days)
- HYFM 7.7K
- PRTG 49.6K
- Earning Date
- HYFM 08-12-2025
- PRTG 09-02-2025
- Dividend Yield
- HYFM N/A
- PRTG N/A
- EPS Growth
- HYFM N/A
- PRTG N/A
- EPS
- HYFM N/A
- PRTG N/A
- Revenue
- HYFM $161,102,000.00
- PRTG N/A
- Revenue This Year
- HYFM $5.45
- PRTG N/A
- Revenue Next Year
- HYFM $5.33
- PRTG N/A
- P/E Ratio
- HYFM N/A
- PRTG N/A
- Revenue Growth
- HYFM N/A
- PRTG N/A
- 52 Week Low
- HYFM $1.50
- PRTG $2.42
- 52 Week High
- HYFM $8.55
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- HYFM 51.00
- PRTG 63.55
- Support Level
- HYFM $4.13
- PRTG $7.58
- Resistance Level
- HYFM $4.73
- PRTG $9.30
- Average True Range (ATR)
- HYFM 0.31
- PRTG 1.03
- MACD
- HYFM -0.03
- PRTG 0.03
- Stochastic Oscillator
- HYFM 45.18
- PRTG 73.85
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.